Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Novel immunosuppressive strategies for bone marrow failure syndromes: a focus on alemtuzumab.
The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade.
Assessment of the effect of interferon-beta1a therapy on thyroid and salivary gland functions in patients with multiple sclerosis using quantitative salivary gland scintigraphyz.
ALAIN01-Alemtuzumab in autoimmune inflammatory neurodegeneration: mechanisms of action and neuroprotective potential.
Double blind placebo-controlled Phase I/II clinical trial of idebenone in patients with primary progressive multiple sclerosis (IPPoMS)
Increase in NF-κB-sensitive miRNA-146a and miRNA-155 in multiple sclerosis (MS) and pro-inflammatory neurodegeneration.
Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration.
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study.
Sex-related factors in multiple sclerosis susceptibility and progression.
Fatigue, depression and sleep disturbances in Iranian patients with multiple sclerosis.
Pelvic Floor Muscle Training With and Without Electrical Stimulation in the Treatment of Lower Urinary Tract Symptoms in Women With Multiple Sclerosis.
Recurrent Nicolau syndrome associated with subcutaneous glatiramer acetate injection-a case report.
Fingolimod phosphate promotes the neuroprotective effects of microglia.
Therapeutic Testosterone Administration Preserves Excitatory Synaptic Transmission in the Hippocampus during Autoimmune Demyelinating Disease.
No impact of adult attachment and temperament on clinical variability in patients with clinically isolated syndrome and early multiple sclerosis.
Genetic analysis of the aquaporin-4 gene for anti-AQP4 antibody-positive neuromyelitis optica in a Japanese population.
Tumefactive multiple sclerosis lesions under fingolimod treatment.
Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks.
Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).
Meralgia paresthetica after subcutaneous injection of glatiramer acetate.
lipid-specific IgM bands in csf associated with a reduced risk of developing pml during treatment with natalizumab.
Confounding in association studies: month of birth and multiple sclerosis.
An Open Label Extension of the LAQ/5062 and LAQ/5063 Studies to Assess the Long Term Safety and Tolerability of Laquinimod 0.6mg in RRMS Patients

Pages